S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
S&P 500   4,567.00 (-1.90%)
DOW   34,483.72 (-1.86%)
QQQ   393.82 (-1.47%)
AAPL   165.30 (+3.16%)
MSFT   330.59 (-1.79%)
FB   324.46 (-4.01%)
GOOGL   2,837.95 (-2.50%)
AMZN   3,507.07 (-1.53%)
TSLA   1,144.76 (+0.68%)
NVDA   326.76 (-2.10%)
BABA   127.53 (-3.10%)
NIO   39.13 (-3.29%)
CGC   10.71 (-3.16%)
AMD   158.37 (-2.19%)
GE   94.99 (-3.47%)
MU   84.00 (-2.48%)
T   22.83 (-4.44%)
F   19.19 (-2.44%)
DIS   144.90 (-1.97%)
ACB   6.42 (-0.31%)
AMC   33.94 (-7.87%)
PFE   53.73 (+2.54%)
BA   197.85 (-0.33%)
NASDAQ:OLMA

Olema Pharmaceuticals Stock Forecast, Price & News

Notice: Trading of Olema Pharmaceuticals halted at 09:33 AM EST due to "LULD pause".
$8.75
-13.14 (-60.03%)
(As of 11/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.57
$13.70
50-Day Range
$20.43
$30.71
52-Week Range
$8.57
$60.27
Volume
10.64 million shs
Average Volume
305,721 shs
Market Capitalization
$352.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive OLMA News and Ratings via Email

Sign-up to receive the latest news and ratings for Olema Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Olema Pharmaceuticals logo

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Headlines

Olema Pharmaceuticals (NASDAQ:OLMA) Hits New 1-Year Low at $19.22
November 23, 2021 |  americanbankingnews.com
Olema Pharmaceuticals (NASDAQ:OLMA) Sees Strong Trading Volume
November 19, 2021 |  americanbankingnews.com
Olema Pharmaceuticals (NASDAQ:OLMA) Shares Down 5.5%
November 17, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OLMA
Phone
N/A
Fax
N/A
Employees
37
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$7.61 per share

Profitability

Net Income
$-22.12 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
30,222,000
Market Cap
$352.52 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
11/30/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/16/2022

MarketRank

Overall MarketRank

2.53 out of 5 stars

Medical Sector

93rd out of 1,390 stocks

Pharmaceutical Preparations Industry

39th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -












Olema Pharmaceuticals (NASDAQ:OLMA) Frequently Asked Questions

Is Olema Pharmaceuticals a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Olema Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Olema Pharmaceuticals stock.
View analyst ratings for Olema Pharmaceuticals
or view top-rated stocks.

Are investors shorting Olema Pharmaceuticals?

Olema Pharmaceuticals saw a increase in short interest in November. As of November 15th, there was short interest totaling 3,310,000 shares, an increase of 22.6% from the October 31st total of 2,700,000 shares. Based on an average daily trading volume, of 383,300 shares, the short-interest ratio is currently 8.6 days. Approximately 10.5% of the company's stock are short sold.
View Olema Pharmaceuticals' Short Interest
.

When is Olema Pharmaceuticals' next earnings date?

Olema Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, March 16th 2022.
View our earnings forecast for Olema Pharmaceuticals
.

How were Olema Pharmaceuticals' earnings last quarter?

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.43) by $0.02.
View Olema Pharmaceuticals' earnings history
.

What price target have analysts set for OLMA?

5 Wall Street analysts have issued 1-year price objectives for Olema Pharmaceuticals' shares. Their forecasts range from $52.00 to $70.00. On average, they anticipate Olema Pharmaceuticals' stock price to reach $60.67 in the next twelve months. This suggests a possible upside of 593.3% from the stock's current price.
View analysts' price targets for Olema Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Olema Pharmaceuticals' key executives?

Olema Pharmaceuticals' management team includes the following people:
  • Dr. Sean P. Bohen, Pres, CEO & Director (Age 54, Pay $643.09k) (LinkedIn Profile)
  • Dr. Cyrus L. Harmon Ph.D., CTO & Director (Age 50, Pay $657.99k)
  • Dr. Peter J. Kushner Ph.D., Chief Scientific Officer (Age 83, Pay $429.95k)
  • Mr. John B. Moriarty Jr., Exec. VP, Chief Legal Officer & Corp. Sec. (Age 53, Pay $434.32k)
  • Mr. Shane William Charles Kovacs M.B.A., COO & CFO (Age 47)
  • Ms. Eva Stroynowski, VP of Communications and Investor Relations
  • Ms. Julie Dexter, VP & Head of People
  • Dr. David C. Myles, Chief Devel. Officer (Age 58)
  • Mr. Kinney Horn, Chief Bus. Officer (Age 47) (LinkedIn Profile)
  • Dr. Pamela M. Klein B.A., M.D., Chief Medical Officer (Age 60)

When did Olema Pharmaceuticals IPO?

(OLMA) raised $170 million in an initial public offering (IPO) on Thursday, November 19th 2020. The company issued 10,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity served as the underwriters for the IPO.

What is Olema Pharmaceuticals' stock symbol?

Olema Pharmaceuticals trades on the NASDAQ under the ticker symbol "OLMA."

Who are Olema Pharmaceuticals' major shareholders?

Olema Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Janus Henderson Group PLC (6.15%), BlackRock Inc. (5.92%), Wellington Management Group LLP (4.17%), Citadel Advisors LLC (3.73%), ArrowMark Colorado Holdings LLC (1.51%) and Geode Capital Management LLC (1.18%). Company insiders that own Olema Pharmaceuticals stock include Cormorant Asset Management, Lp, Cyrus Harmon, G Walmsley Graham, Kinney Horn and Sean Bohen.
View institutional ownership trends for Olema Pharmaceuticals
.

Which major investors are selling Olema Pharmaceuticals stock?

OLMA stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Invesco Ltd., Sectoral Asset Management Inc, Morgan Stanley, HighVista Strategies LLC, Candriam Luxembourg S.C.A., and California State Teachers Retirement System. Company insiders that have sold Olema Pharmaceuticals company stock in the last year include Cyrus Harmon, Kinney Horn, and Sean Bohen.
View insider buying and selling activity for Olema Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Olema Pharmaceuticals stock?

OLMA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., ArrowMark Colorado Holdings LLC, Geode Capital Management LLC, Russell Investments Group Ltd., Goldman Sachs Group Inc., Two Sigma Investments LP, Renaissance Technologies LLC, and Bank of New York Mellon Corp. Company insiders that have bought Olema Pharmaceuticals stock in the last two years include Cormorant Asset Management, Lp, and G Walmsley Graham.
View insider buying and selling activity for Olema Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Olema Pharmaceuticals?

Shares of OLMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Olema Pharmaceuticals' stock price today?

One share of OLMA stock can currently be purchased for approximately $8.75.

How much money does Olema Pharmaceuticals make?

Olema Pharmaceuticals has a market capitalization of $352.52 million. The company earns $-22.12 million in net income (profit) each year or ($1.76) on an earnings per share basis.

How many employees does Olema Pharmaceuticals have?

Olema Pharmaceuticals employs 37 workers across the globe.

What is Olema Pharmaceuticals' official website?

The official website for Olema Pharmaceuticals is www.olema.com.

Where are Olema Pharmaceuticals' headquarters?

Olema Pharmaceuticals is headquartered at 512 2ND STREET 4TH FLOOR, SAN FRANCISCO CA, 94107.

How can I contact Olema Pharmaceuticals?

Olema Pharmaceuticals' mailing address is 512 2ND STREET 4TH FLOOR, SAN FRANCISCO CA, 94107. The company can be reached via email at [email protected].


This page was last updated on 11/30/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.